Back to home

Easyhaler® product family

Product info | 17/09/2021

easyhaler-cell.png

Fusacomb_down.png

Fobumix_down.png

Salbutamol_down.png

Formoterol_down.png

Budesonide_down.png

Beclometasone_down.png

Easyhaler® is the first inhaler range to be certified as carbon neutral1

The Easyhaler® product family provides a selection of treatment options for both asthma and COPD patients available in a dry powder inhaler form:

eh-violet-symbol.png Inhaled Corticosteroids
eh-violet-symbol.png Short acting beta agonist
eh-violet-symbol.png Long acting beta agonist
eh-violet-symbol.png Inhaled corticosteroid + long acting beta agonist

COPD = Chronic obstructive pulmonary disease, ICS = Inhaled corticosteroid, SABA = Short acting beta agonist, LABA = Long acting beta agonist, ICS + LABA = Inhaled corticosteroid + long acting beta agonist, FEV1 = Forced expiratory volume in the first second

 

References:
1. Carbon Neutral Certificate for Easyhaler product range. Orion Pharma. Data on file. 

 

October 2021 / RESP-330bbc(3)

 

Adverse events should be reported. Reporting forms and information
can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Orion Pharma (UK) Ltd on 01635 520300.
 

 

Fusacomb_top.png

PRESENTATIONS:
Salmeterol/fluticasone propionate 50/250mcg and 50/500mcg per dose.

AGE:
Adults and adolescents 12 years and older

STRENGTHS (ACTUATIONS), PRICE:
50/250 mcg (60), £21.50
50/500 mcg (60), £26.99

INDICATION:
Asthma all strengths:
Indicated in adults and adolescents 12 years and older. Regular treatment of asthma where use of a combination product (long-acting ß2 agonist and inhaled corticosteroid) is appropriate:

patients not adequately controlled with
inhaled corticosteroids and ‘as needed’
inhaled short-acting ß2 agonist

or

patients already adequately controlled
on both inhaled corticosteroid and long
acting-beta-2 agonist.

 

COPD: (50/500mcg only):
Symptomatic treatment of patients with COPD, with a FEV1<60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.

CONTRAINDICATIONS:
Fusacomb Easyhaler is contraindicated in patients with hypersensitivity to salmeterol, fluticasone propionate, lactose or milk proteins.

UNDESIRABLE EFFECTS:
As Fusacomb Easyhaler contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. There is no incidence of additional adverse events following concurrent administration of the two compounds.

ADVERSE EVENTS:
Very common:
Nasopharyngitis, headaches.
Common:
Candidiasis of the mouth and throat, Pneumonia (in COPD patients), Bronchitis, Hypokalaemia, Throat irritation, hoarseness/dysphonia, Sinusitis, Contusions, Muscle cramps, Traumatic fractures, Arthralgia, Myalgia.

Prescribers should consult the SmPC in relation to other side effects.

Read more about Fusacomb Easyhaler here.

top.png

October 2021 / RESP-330bbc(3)a

Fusacomb_bottom.png

Fobumix_top.png

PRESENTATIONS:
Budesonide and formoterol fumarate
dihydrate 80/4.5mcg, 160/4.5mcg and
320/9mcg per dose.

AGE:
Adults 18 years of age and older only.

STRENGTHS (ACTUATIONS), PRICE:
80/4.5 mcg (120), £21.50
160/4.5 mcg (60), £10.75
160/4.5 mcg (120), £21.50
320/9 mcg (60), £21.50

INDICATIONS:
Asthma all strengths: 
Indicated in adults (18 years and older) for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting ß2 adrenoceptor agonist) is appropriate:

patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting ß2 adrenoceptor agonists

or

patients already adequately controlled on both inhaled corticosteroids and long-acting ß2 adrenoceptor agonists

Note: Fobumix Easyhaler 80mcg/4.5mcg is not appropriate in patients with severe asthma.

 

COPD (160/4.5mcg & 320/9mcg only):
Symptomatic treatment of adults (18 years and older) with COPD with FEV1 < 70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy.

CONTRAINDICATIONS:
Fobumix Easyhaler is contraindicated in patients with hypersensitivity to budesonide, formoterol, lactose or milk proteins.

UNDESIRABLE EFFECTS:
Since Fobumix Easyhaler contains both
budesonide and formoterol, the same
pattern of undesirable effects as reported for these substances may occur.

No increased incidence of adverse reactions has been seen following concurrent administration of the two compounds. The most common drug related adverse reactions are pharmacologically predictable side-effects of ß2 agonist therapy, such as tremor and palpitations. These tend to be mild and usually disappear within a few days of treatment.

ADVERSE EVENTS:
Common:
Candida infections in the oropharynx, headache, tremor, palpitations, mild irritation in the throat, coughing, dysphonia including hoarseness.

Prescribers should consult the SmPC in relation to other side effects

Read more about Fobumix Easyhaler here. top.png
October 2021 / RESP-330bbc(3)b
Fobumix_bottom.png

Fusacomb_top.png

PRESENTATIONS:
Salbutamol 100mcg and 200mcg per dose.

AGE:
Adults and children aged 4 years and over

STRENGTHS (ACTUATIONS), PRICE:
100 mcg (200), £3.31
200 mcg (200), £6.63

INDICATION:
Symptomatic treatment of asthma attacks and exacerbations of asthma in adults and children aged 4 years and over; prevention of exercise-induced bronchospasm or before unavoidable allergen exposure; symptomatic treatment of broncho-asthma and other conditions associated with reversible airways obstruction.

 

CONTRAINDICATIONS:
Easyhaler Salbutamol is contraindicated in patients with hypersensitivity to salbutamol, lactose or milk proteins. Not for management of premature labour or threatened abortion.

UNDESIRABLE EFFECTS:
The undesirable effects caused by normally used inhaled doses of salbutamol are mild, typical for sympathomimetic agents, and they usually disappear with continued treatment.

ADVERSE EVENTS:
Common:
Tremors, palpitations.

Prescribers should consult the SmPC in relation to other side effects.

October 2021 / RESP-330bbc(3)c top.png
Salbutamol_bottom.png

Formoterol_top.png

PRESENTATIONS:
Formoterol fumarate dihydrate 12 mcg per dose.

AGE:
Adults and children aged 6 years and over.

STRENGTHS (ACTUATIONS), PRICE:
12 mcg (120), £23.75

INDICATION:
Treatment of asthma in patients treated
with inhaled corticosteroids and who
also require a long-acting ß2-agonist;
relief of reversible airways obstruction in
patients with obstruction in adult patients with COPD needing long-term
bronchodilators.

 

CONTRAINDICATIONS:
Formoterol Easyhaler is contraindicated in patients with hypersensitivity to formoterol, lactose or milk proteins.

UNDESIRABLE EFFECTS:
The most commonly reported adverse events of ß2-agonist therapy, such as tremor and palpitations, tend to be mild and disappear within a few days of treatment.

ADVERSE EFFECTS:
Common: 
Headache, tremor, palpitations.

Prescribers should consult the SmPC in relation to other side effects.

October 2021 / RESP-330bbc(3)d top.png
Formoterol_bottom.png

Budesonide_top.png

PRESENTATIONS:
Budesonide 100 mcg, 200 mcg and 400 mcg per dose

AGE:
Adults and children aged 6 years and over.

STRENGTHS (ACTUATIONS), PRICE:
100 mcg (200), £8.86
200 mcg (200), £17.71
400 mcg (100), £17.71

 

INDICATION:
Treatment of mild, moderate or severe persistent asthma.

CONTRAINDICATIONS:
Easyhaler Budesonide is contraindicated in patients with hypersensitivity to budesonide, lactose or milk proteins.

ADVERSE EVENTS:
Common:
Oropharyngeal candidiasis, cough, throat irritation, difficulty in swallowing.

Prescribers should consult the SmPC in relation to other side effects

Read more about Easyhaler Budesonide here.

October 2021 / RESP-330bbc(3)e

top.png
Budesonide_bottom.png

Beclometasone_top.png

PRESENTATIONS:
Beclometasone 200 mcg per dose.

AGE:
Adults only (not indicated for use in children).

STRENGTHS (ACTUATIONS), PRICE:
200 mcg (200), £14.93

INDICATION:
Prophylactic management of mild, moderate, or severe asthma in adults.

 

CONTRAINDICATIONS:
Easyhaler Beclometasone is contraindicated in patients with hypersensitivity to beclometasone,
lactose or milk proteins. Special care in patients with active or quiescent pulmonary tuberculosis.

ADVERSE EVENTS:
Very common:
Candidiasis of the mouth and throat.

Common: Hoarseness/throat irritation, cough.

Prescribers should consult the SmPC in relation to other side effects.

October 2021 / RESP-330bbc(3)f top.png
Beclometasone_bottom.png

ORIONPHARMA.CO.UK

 

Full prescribing information available here

 

MAY 2021 / RESP-330b(3)

 

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Orion Pharma (UK) Ltd on 01635 520300.

Orion Pharma (UK) Ltd, Abbey Gardens, 4 Abbey Street, Reading, RG1 3BA, UK | Tel: +44 1635 520 300 | February 2021 / RESP-330(1)
Policies Contact us Orion Corporation 2021